Publication details
Efekt erlotinibu u pacientů se spinocelulárním karcinomem plic ve 2. a 3. linii protinádorové léčby - kazuistická sdělení
| Title in English | Effect of Erlotinib in 2nd and 3rd Line Anticancer Treatment in Patients with Squamous Cell Lung Cancer – Case Series |
|---|---|
| Authors | |
| Year of publication | 2017 |
| Type | Article in Periodical |
| Magazine / Source | Klinická onkologie |
| MU Faculty or unit | |
| Citation | |
| Doi | http://dx.doi.org/10.14735/amko2017131 |
| Field | Oncology and hematology |
| Keywords | non-small cell lung cancer; squamous carcinoma; erlotinib; treatment; tyrosine kinase inhibitor |
| Description | Squamous cell carcinoma of the lung (SCC) represents cca 30–40% of new cases of non-small cell lung cancer (NSCLC) in the Czech Republic. The tyrosine kinase inhibitor erlotinib is indicated as a 1st line treatment for patients with locally advanced and metastatic disease and activating mutations in endothelial growth factor receptor (EGFR), or as a 2nd or 3rd line treatment in EGFR-negative NSCLC patients after chemotherapeutic failure. |